Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 11:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 4,802 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Allergy Clear all
Completed No phase listed Observational Accepts healthy volunteers

Visual Discomfort and Reading

NCT00402155
View directory record Official record
Conditions
Visual Fatigue
Interventions
Stress on visual discomfort
Behavioral
Lead sponsor
Southern California College of Optometry at Marshall B. Ketchum University
Other
Eligibility
17 Years to 30 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Claremont, California
Source: ClinicalTrials.gov public record
Updated Nov 13, 2009 · Synced Oct 21, 2026, 11:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving Parent Understanding of Instructions About Asthma Care

NCT01405625
View directory record Official record
Conditions
Asthma
Interventions
Pictogram-based asthma action plan, AAAAI standard of care written action plan
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
Not listed
Enrollment
449 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 5, 2018 · Synced Oct 21, 2026, 11:10 PM EDT
Terminated Phase 4 Interventional Results available

Effect of Bradykinin Receptor Antagonism on ACE Inhibitor-associated Angioedema

NCT01574248
View directory record Official record
Conditions
ACE Inhibitor-associated Angioedema
Interventions
icatibant, Placebo
Drug · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
San Diego, California • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 17, 2017 · Synced Oct 21, 2026, 11:10 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines

NCT05976243
View directory record Official record
Conditions
Chronic Inducible Urticaria
Interventions
Remibrutinib, Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
25
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Bakersfield, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 21, 2026, 11:10 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma

NCT05851443
View directory record Official record
Conditions
Moderate to Severe Asthma
Interventions
povorcitinib, placebo, ICS-LABA
Drug · Other
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
26
States / cities
Birmingham, Alabama • Bakersfield, California • Upland, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 21, 2026, 11:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Broccoli Sprout Extract Effects on Allergic Inflammation in the Nose

NCT00882115
View directory record Official record
Conditions
Allergic Airway Disease
Interventions
Broccoli sprout extract (BSE)
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 20, 2019 · Synced Oct 21, 2026, 11:10 PM EDT
Completed Phase 4 Interventional Results available

Management of Pruritus With Xyzal in Atopic Dermatitis

NCT00884325
View directory record Official record
Conditions
Atopic Dermatitis, Pruritus
Interventions
Levocetirizine dihydrochloride (Xyzal), placebo
Drug
Lead sponsor
Derm Research, PLLC
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 16, 2013 · Synced Oct 21, 2026, 11:10 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of ACZ885 in Patients With Muckle-Wells Syndrome

NCT00465985
View directory record Official record
Conditions
Muckle Wells Syndrome
Interventions
ACZ885, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
4 Years to 75 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
3
States / cities
San Francisco, California • Chicago, Illinois • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 28, 2017 · Synced Oct 21, 2026, 11:10 PM EDT
Completed Phase 1 Interventional

A Study Evaluating Potential Disease-Mediated Drug-Drug Interaction in Adult Participants With Active Eosinophilic Esophagitis Receiving Cendakimab

NCT05175352
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Cendakimab, CYP substrates
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
12
States / cities
Tucson, Arizona • Los Angeles, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2024 · Synced Oct 21, 2026, 11:10 PM EDT
Completed Not applicable Interventional

Formula for Children With Cow's Milk Allergy

NCT02317952
View directory record Official record
Conditions
Milk Allergy
Interventions
Experimental Extensively Hydrolyzed Formula, Active Comparator Formula
Other
Lead sponsor
Perrigo Nutritionals
Industry
Eligibility
Up to 13 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
18
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Huntington Beach, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Oct 21, 2026, 11:10 PM EDT
Terminated Phase 2 Interventional

Efficacy and Safety Study of TOLAMBA™ in Ragweed-Allergic Adults

NCT00387738
View directory record Official record
Conditions
Rhinitis, Allergic, Seasonal
Interventions
Amb a 1 immunostimulatory oligodeoxyribonucleotide conjugate, Histamine base
Biological
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
738 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
28
States / cities
Oxford, Alabama • Stockbridge, Georgia • Normal, Illinois + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 21, 2026, 11:10 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Recurrent Urinary Tract Infections and the Microbiome

NCT04831840
View directory record Official record
Conditions
Recurrent Urinary Tract Infection
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
2
States / cities
Fort Lauderdale, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Oct 21, 2026, 11:10 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants

NCT03387852
View directory record Official record
Conditions
Asthma
Interventions
SAR440340, Dupilumab, Fluticasone or Fluticasone/salmeterol combination, Placebo for SAR440340, Placebo for dupilumab
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
18
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Oct 21, 2026, 11:10 PM EDT
Completed Not applicable Interventional Results available

High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

NCT03389347
View directory record Official record
Conditions
Plasma Cell Leukemia, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Biospecimen Collection, High Throughput Screening, Laboratory Biomarker Analysis
Procedure · Device · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 21, 2026, 11:10 PM EDT
Active, not recruiting Not applicable Interventional

Evaluating the Influence of Diet-induced Weight Loss on Fat (Adipose) Tissue's Insulin Sensitivity and Testosterone Synthesis in Women With Overweight or Obesity, Insulin Resistance, and Hyperandrogenemia

NCT06998238
View directory record Official record
Conditions
Overweight and Obesity, Hyperandrogenemia, Insulin Resistance
Interventions
Mediterranean-based, carbohydrate restricted, calorie reduced diet
Behavioral
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
21 Years to 45 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 21, 2026, 11:10 PM EDT
Recruiting Phase 2 Interventional

FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial

NCT06244004
View directory record Official record
Conditions
Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Antiandrogen Therapy, Bone Scan, Computed Tomography, Cytotoxic Chemotherapy, FDG-Positron Emission Tomography, Radiation Therapy
Drug · Procedure · Radiation
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Male only
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
6
States / cities
Chicago, Illinois • DeKalb, Illinois • Geneva, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 21, 2026, 11:10 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Accuracy of the Red Reflex Test in the Pediatric Population

NCT04125043
View directory record Official record
Conditions
Abnormal Vitreous Humor Morphology, Abnormal Choroid Morphology, Optic Nerve Diseases, Retinal Disease, Retinal Hemorrhage
Interventions
Direct ophthalmoscope
Diagnostic Test
Lead sponsor
Children's National Research Institute
Other
Eligibility
Up to 18 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Oct 21, 2026, 11:10 PM EDT
Recruiting Phase 3 Interventional

A Study to Learn About the Study Medicine Called Tilrekimig ( PF-07275315) in People With Severe Asthma

NCT07869043
View directory record Official record
Conditions
Asthma
Interventions
tilrekimig, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 80 Years
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Pittsburgh, Pennsylvania • Austin, Texas • Tomball, Texas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 21, 2026, 11:10 PM EDT
Completed Not applicable Interventional

Oral Probiotic Administration to Modulate the Airway Microbiome in Obese Asthmatic Subjects

NCT03157518
View directory record Official record
Conditions
Asthma
Interventions
Seeking Health Probiota Bifido
Dietary Supplement
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 99 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 20, 2018 · Synced Oct 21, 2026, 11:10 PM EDT
Completed No phase listed Observational

Long-Term Sequelae of SARS-COV-2 Infection: Diabetes Mellitus

NCT05867017
View directory record Official record
Conditions
COVID-19, Diabete Mellitus
Interventions
Measure of physiologic parameters
Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 75 Years
Enrollment
23 participants
Timeline
2023 – 2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 21, 2026, 11:10 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

High Resolution Phenotyping in Healthy Humans

NCT00943774
View directory record Official record
Conditions
Pressor Response, Baroreflex Sensitivity, Blood Pressure Variability, Heart Rate Variability, Arterial Catecholamines
Interventions
Physiological maneuvers
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 50 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 6, 2016 · Synced Oct 21, 2026, 11:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effectiveness of Two Water-Based Potassium Oxalate Desensitizers on Dental Hypersensitivity

NCT02152826
View directory record Official record
Conditions
Dentin Sensitivity
Interventions
Potassium oxalate
Device
Lead sponsor
Procter and Gamble
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 18, 2020 · Synced Oct 21, 2026, 11:10 PM EDT
Completed No phase listed Observational

Association Between Vitamin D and Inflammation and Diabetes Risk in Morbidly Obese Pre-Menopausal Women

NCT02169050
View directory record Official record
Conditions
Insulin Sensitivity
Interventions
Not listed
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
21 Years to 49 Years · Female only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 21, 2026, 11:10 PM EDT
Completed Phase 3 Interventional Results available

S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer

NCT01809691
View directory record Official record
Conditions
Prostate Cancer
Interventions
TAK-700, Bicalutamide
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older · Male only
Enrollment
1,313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
560
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 374 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 21, 2026, 11:10 PM EDT